Item 7.01 Regulation FD Disclosure

On May 2, 2022, Alaunos Therapeutics, Inc. (the "Company") issued a press release announcing a poster presentation at the 25th Annual Meeting of the American Society of Gene and Cell Therapy discussing new preclinical data from the Company's membrane-bound interleukin-15 program. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information contained in this Item 7.01, including Exhibit 99.1, is being "furnished" and shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The information contained in this Item 7.01, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Item 9.01 Financial Statements and Exhibits




(d) Exhibits.

Exhibit
  No.        Description

99.1           Press Release, dated May 2, 2022.

104          Cover Page Interactive Data File (embedded within the Inline XBRL
             document).

--------------------------------------------------------------------------------

© Edgar Online, source Glimpses